BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Patel D, Bertz R, Ren S, Boulton DW, Någård M. A Systematic Review of Gastric Acid-Reducing Agent-Mediated Drug-Drug Interactions with Orally Administered Medications. Clin Pharmacokinet 2020;59:447-62. [PMID: 31788764 DOI: 10.1007/s40262-019-00844-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
Number Citing Articles
1 Saiz Ladera GM, Pejenaute Labari ME, García Pascual JN. [Updating in prescription of proton pump inhibitors. What to do and what not to do]. Semergen 2021;47:267-79. [PMID: 33223372 DOI: 10.1016/j.semerg.2020.09.011] [Reference Citation Analysis]
2 Mudie DM, Stewart AM, Rosales JA, Biswas N, Adam MS, Smith A, Craig CD, Morgen MM, Vodak DT. Amorphous Solid Dispersion Tablets Overcome Acalabrutinib pH Effect in Dogs. Pharmaceutics 2021;13:557. [PMID: 33921109 DOI: 10.3390/pharmaceutics13040557] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Pathomthongtaweechai N, Muanprasat C. Potential Applications of Chitosan-Based Nanomaterials to Surpass the Gastrointestinal Physiological Obstacles and Enhance the Intestinal Drug Absorption. Pharmaceutics 2021;13:887. [PMID: 34203816 DOI: 10.3390/pharmaceutics13060887] [Reference Citation Analysis]
4 Xu H, O'Gorman M, Matschke K, Boutros T, Brega N, Tan W, Bello A. Evaluation of Proton Pump Inhibitor Esomeprazole on Crizotinib Pharmacokinetics in Healthy Participants. Clin Pharmacol Drug Dev 2021. [PMID: 34825782 DOI: 10.1002/cpdd.1032] [Reference Citation Analysis]
5 Miao L, Wu F, Yang X, Mousa YM, Ramamoorthy A, Lee S, Raines K, Zhang L, Seo P. Application of Solubility and Dissolution Profile Comparison for Prediction of Gastric pH-Mediated Drug-Drug Interactions. AAPS J 2022;24. [DOI: 10.1208/s12248-022-00684-3] [Reference Citation Analysis]
6 Garg V, Narang P, Taneja R. Antacids revisited: review on contemporary facts and relevance for self-management. J Int Med Res 2022;50:3000605221086457. [PMID: 35343261 DOI: 10.1177/03000605221086457] [Reference Citation Analysis]
7 Kanukula R, Salam A, Rodgers A, Kamel B. Pharmacokinetics of Rosuvastatin: A Systematic Review of Randomised Controlled Trials in Healthy Adults. Clin Pharmacokinet 2021;60:165-75. [PMID: 33428168 DOI: 10.1007/s40262-020-00978-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Wong S, Krejsa C, Lee D, Harris A, Simard E, Wang X, Allard M, Podoll T, O'Reilly T, Slatter JG. Pharmacokinetics and Macrophage Inhibitory Cytokine-1 Pharmacodynamics of the Murine Double Minute 2 Inhibitor, Navtemadlin (KRT-232) in Fed and Fasted Healthy Subjects. Clin Pharmacol Drug Dev 2022. [PMID: 35172043 DOI: 10.1002/cpdd.1070] [Reference Citation Analysis]
9 Maher D, Ailabouni N, Mangoni AA, Wiese MD, Reeve E. Alterations in drug disposition in older adults: a focus on geriatric syndromes. Expert Opin Drug Metab Toxicol 2021;17:41-52. [PMID: 33078628 DOI: 10.1080/17425255.2021.1839413] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
10 Xu H, O'Gorman MT, Nepal S, James LP, Ginman K, Pithavala YK. Phase 1 Study Evaluating the Effects of the Proton Pump Inhibitor Rabeprazole and Food on the Pharmacokinetics of Lorlatinib in Healthy Participants. Clin Pharmacol Drug Dev 2021. [PMID: 34288547 DOI: 10.1002/cpdd.1000] [Reference Citation Analysis]
11 Pounina TA, Gloriozova TA, Savidov N, Dembitsky VM. Sulfated and Sulfur-Containing Steroids and Their Pharmacological Profile. Mar Drugs 2021;19:240. [PMID: 33923288 DOI: 10.3390/md19050240] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Murakami T, Bodor E, Bodor N. Factors and dosage formulations affecting the solubility and bioavailability of P-glycoprotein substrate drugs. Expert Opin Drug Metab Toxicol 2021;17:555-80. [PMID: 33703995 DOI: 10.1080/17425255.2021.1902986] [Reference Citation Analysis]
13 Loisios-Konstantinidis I, Dressman J. Physiologically Based Pharmacokinetic/Pharmacodynamic Modeling to Support Waivers of In Vivo Clinical Studies: Current Status, Challenges, and Opportunities. Mol Pharm 2021;18:1-17. [PMID: 33320002 DOI: 10.1021/acs.molpharmaceut.0c00903] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
14 Mohylyuk V, Yerkhova A, Katynska M, Sirko V, Patel K. Effect of Elevated pH on the Commercial Enteric-Coated Omeprazole Pellets Resistance: Patent Review and Multisource Generics Comparison. AAPS PharmSciTech 2021;22:188. [PMID: 34159427 DOI: 10.1208/s12249-021-02038-2] [Reference Citation Analysis]
15 Matsumura N, Ono A, Akiyama Y, Fujita T, Sugano K. Bottom-Up Physiologically Based Oral Absorption Modeling of Free Weak Base Drugs. Pharmaceutics 2020;12:E844. [PMID: 32899235 DOI: 10.3390/pharmaceutics12090844] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kaur Mukker J, Dukes G, Wang L, Huh S, Khudyakov P, Nishihara M, Chen C. Evaluation of the pharmacokinetics of trazpiroben (TAK-906) in the presence and absence of the proton pump inhibitor esomeprazole. Clin Transl Sci 2022. [PMID: 35218604 DOI: 10.1111/cts.13248] [Reference Citation Analysis]
17 Mudie DM, Stewart AM, Rosales JA, Adam MS, Morgen MM, Vodak DT. In Vitro-In Silico Tools for Streamlined Development of Acalabrutinib Amorphous Solid Dispersion Tablets. Pharmaceutics 2021;13:1257. [PMID: 34452217 DOI: 10.3390/pharmaceutics13081257] [Reference Citation Analysis]
18 Bridoux M, Simon N, Turpin A. Proton Pump Inhibitors and Cancer: Current State of Play. Front Pharmacol 2022;13:798272. [DOI: 10.3389/fphar.2022.798272] [Reference Citation Analysis]
19 Hodges P, Kelly P, Kayamba V. Helicobacter pylori infection and hypochlorhydria in Zambian adults and children: A secondary data analysis. PLoS One 2021;16:e0256487. [PMID: 34449790 DOI: 10.1371/journal.pone.0256487] [Reference Citation Analysis]
20 Bouajram RH, Awdishu L. A Clinician's Guide to Dosing Analgesics, Anticonvulsants, and Psychotropic Medications in Continuous Renal Replacement Therapy. Kidney Int Rep 2021;6:2033-48. [PMID: 34386653 DOI: 10.1016/j.ekir.2021.05.004] [Reference Citation Analysis]
21 Van Camp A, Vanuytsel T, Brouwers J, Augustijns P. The effect of esomeprazole on the upper GI tract release and systemic absorption of mesalazine from colon targeted formulations. Int J Pharm 2022;:121701. [PMID: 35339635 DOI: 10.1016/j.ijpharm.2022.121701] [Reference Citation Analysis]